Towards Multi-Modality Therapy for Marfan Syndrome: Synergistic Effect of Angiotensin and TRPC4 Receptor Blockade on Ascending Aortic Aneurysms

Nicholas B. Cavanaugh  
*Marian University - Indianapolis, Duke University Department of Surgery, Durham, NC, ncavanaugh122@marian.edu*

Lan Qian MBBS  
*Caver College of Medicine, Iowa City, IA*

Nicole M. Westergaard  
*Caver College of Medicine, Iowa City, IA*

Joseph W. Turek MD, Ph.D.  
*Duke University Department of Surgery, Durham, NC*

Follow this and additional works at:  [https://mushare.marian.edu/mucom_rd](https://mushare.marian.edu/mucom_rd)

Part of the Medicine and Health Sciences Commons

**Recommended Citation**

Cavanaugh, Nicholas B.; Qian, Lan MBBS; Westergaard, Nicole M.; and Turek, Joseph W. MD, Ph.D., "Towards Multi-Modality Therapy for Marfan Syndrome: Synergistic Effect of Angiotensin and TRPC4 Receptor Blockade on Ascending Aortic Aneurysms" (2017). MU-COM Research Day. 46.  
[https://mushare.marian.edu/mucom_rd/46](https://mushare.marian.edu/mucom_rd/46)

This Poster is brought to you for free and open access by the College of Osteopathic Medicine at MUSHare. It has been accepted for inclusion in MU-COM Research Day by an authorized administrator of MUSHare. For more information, please contact emandity@marian.edu.
Towards Multi-Modality Therapy for Marfan Syndrome: Synergistic Effect of Angiotensin and TRPC4 Receptor Blockade on Ascending Aortic Aneurysms

Cavanaugh NB, Dyle MC, Qian L, Westergaard NM, and Turek JW
Pediatric Cardiac Surgery, University of Iowa Stead Family Children’s Hospital, Iowa City, IA

Background

Marfan syndrome (MFS) is a genetic disease that commonly presents with aortopathy. While promising therapies have been studied, complete attenuation of MFS-induced aortic aneurysms in the clinical arena has been elusive. The presence of significant, not-yet-described MFS signaling pathways has been suggested as a reason for the less than ideal clinical response to single drug therapy. Transient receptor potential (TRP) channels have emerged as likely regulators of vascular smooth muscle cell (VSMC) activity. In this regard, they are abundantly found in VSMCs and are associated with increased matrix metalloproteinase 9 activity. The current study seeks to explore the role of TRP channels in MFS.

Methods

A Fbn1C1039G/+ heterozygous mouse, with a mutation in fibrillin-1, was supplemented with angiotensin II (4.5 mg/kg/day) to accelerate aneurysmal formation. Mice analyzed were wild type (wt) (saline +/- angiotensin II) and heterozygous (saline +/- angiotensin II). Quantitative PCR and western blotting was used to examine differential expression of TRP channels across the various cohorts. The TRPC4 antagonist, ML204 (10mg/kg/day), was given daily during two weeks of angiotensin II infusion. Mice were echoed before and after to assess aortic diameter.

Results

Quantitative PCR of the accelerated model revealed a near 10-fold increase in TRPC4 transcription with respect to wt mice. ML204 and losartan worked synergistically to ameliorate aortic dilation.

This figure represents relative transcription of transient receptor potential channels with normalization to wt mice in triplicate.

Murine Model Aortic Diameter

This figure represents the percent change in aortic diameter over 14 days following pharmacologic intervention of an accelerated MFS mouse with the use of losartan (LT) and ML204 (ML).*indicates significance of P<.05 as compared to other groups.

Conclusions

These studies suggest a complementary role for TRPC4 in MFS-induced aortic pathology. Antagonism of this novel target shows promise toward multi-drug therapy for the treatment of aortic aneurysms in MFS.

References


% Increase in Aortic Diameter over 14 days

% Increase in Aortic Diameter over 14 days

Reference